Listen
CETINOR (sildenafil), phosphodiesterase type 5 inhibitor
UROLOGY - New medicinal product
Opinions on drugs -
Posted on
May 10 2017
Reason for request
Inclusion
- CETINOR has marketing authorisation in adult men with erectile dysfunction.
- It is a 1st-line medicine that has no clinical added value compared with other phosphodiesterase type 5 inhibitors (CIALIS, LEVITRA, SPEDRA).
- Reimbursement is recommended only in men whose erectile dysfunction is very likely to be causally related to a serious and defined organic disease.
Clinical Benefit
| Substantial |
- |
| Insufficient |
Clinical Added Value
| no clinical added value |
- |
Therapeutic use
- |
English version
Contact Us
Évaluation des médicaments
